Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade

ConclusionsTaken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells.

http://link.springer.com/10.1007/s13402-017-0318-8

Source: Cellular Oncology - April 11, 2017 Category: Cancer & Oncology Source Type: research